Lentiviral miR30-based RNA interference against heparanase suppresses melanoma metastasis with lower liver and lung toxicity

International Journal of Biological Sciences

Volumn 9, Issue 6, 2013, Pages 564-577

  Liu, Xiao Yan ^a   Tang, Qiu Su ^b   Chen, Hong Chao ^a   Jiang, Xiao LIng ^a   Fang, Hong ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Heparanase; Metastasis; microRNA(miRNA); RNA interference; Safety

Indexed keywords

BETA GLUCURONIDASE; HEPARANASE; MICRORNA; SMALL INTERFERING RNA;

ANIMAL; ARTICLE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE VECTOR; GENETICS; HUMAN; LENTIVIRINAE; LIVER; LUNG; MELANOMA; METASTASIS; MICRORNA(MIRNA); MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SAFETY; TUMOR CELL LINE;

HEPARANASE; METASTASIS; MICRORNA(MIRNA); RNA INTERFERENCE; SAFETY;

ANIMALS; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC VECTORS; GLUCURONIDASE; HUMANS; LENTIVIRUS; LIVER; LUNG; MELANOMA; MICE; MICRORNAS; NEOPLASM METASTASIS; REAL-TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING;

LENTIVIRUS;

EID: 84879322199     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.5425     Document Type: Article

References (61)

1. Abboud-Jarrous G, Atzmon R, Peretz T, et al. Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment. J Biol Chem. 2008; 283:18167-76.
2. Barash U, Cohen-Kaplan V, Dowek I, et al. Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J. 2010; 277: 3890-903.
3. Kudchadkar R, Gonzalez R, Lewis KD. PI-88: a novel inhibitor of angiogenesis. Expert Opin Investig Drugs. 2008; 17:1769-76.
4. Khasraw M, Pavlakis N, McCowatt S, et al. Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Ann Oncol. 2010; 21: 1302-7.
5. Tan FL, Yin JQ. RNAi, a new therapeutic strategy against viral infection. Cell Res. 2004; 14: 460-6.
6. Liu XY, Fang H, Yang ZG, et al. Construction of small interfering RNA targeting heparanase gene and its inhibitory effect on the invasiveness of human malignant melanoma cell line A375 in vitro. Chin J Dermatol. 2007; 11: 676-9.
7. Leung RK, Whittaker PA. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol Ther. 2005; 107: 222-39.
8. Akhtar S, Benter IF. Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest. 2007; 117: 3623-32.
9. Yuan J, Wang X, Zhang Y, et al. shRNA transcribed by RNA Pol II promoter induce RNA interference in mammalian cell. Mol Biol Rep. 2006; 33: 43-9.
10. Scherr M, Eder M. Gene silencing by small regulatory RNAs in mammalian cells. Cell Cycle. 2007; 6: 444-9.
11. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281-97.
12. Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004; 23: 4051-60.
13. Dickins RA, McJunkin K, Hernando E, et al. Tissue-specific and reversible RNA interference in transgenic mice. Nat Genet. 2007; 39: 914-21.
14. Snyder LL, Esser JM, Pachuk CJ, et al. Vector design for liver-specific expression of multiple interfering RNAs that target hepatitis B virus transcripts. Antiviral Res. 2008; 80: 36-44.
15. Shin KJ, Wall EA, Zavzavadjian JR, et al. A single lentiviral vector platform for microRNA-based conditional RNA interference and coordinated transgene expression. Proc Natl Acad Sci U S A. 2006; 103: 13759-64.
16. Wu J, Bonsra AN, Du G. pSM155 and pSM30 vectors for miRNA and shRNA expression. Methods Mol Biol. 2009; 487:205-19.
17. Sun BS, Dong QZ, Ye QH, et al. Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology. 2008; 48:1834-42.
18. Stegmeier F, Hu G, Rickles RJ, et al. A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci U S A. 2005; 102: 13212-7.
19. McBride JL, Boudreau RL, Harper SQ, et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A. 2008; 105: 5868-73.
20. Bauer M, Kinkl N, Meixner A, et al. Prevention of interferon-stimulated gene expression using microRNA-designed hairpins. Gene Therapy. 2009; 16:142-7.
21. Jose MS, Mamie ZL, Ken Chang, et al. Second-generation shRNA libraries covering the mouse and human genomes. Nature genetics. 2005; 37:1281-7.
22. Liu X, Fang H, Chen H, et al. An Artificial miRNA against HPSE Suppresses Melanoma Invasion Properties, Correlating with a Down-Regulation of Chemokines and MAPK Phosphorylation. PLoS One. 2012; 7:e38659.
23. Lu TS, Yiao SY, Lim K, et al. Interpretation of biological and mechanical variations between the Lowry versus Bradford method for protein quantification. N Am J Med Sci. 2010; 2:325-8.
24. Sui M, Xiong X, Kraft AS, et al. Combination of gemcitabine antagonizes antitumor activity of paclitaxel through prevention of mitotic arrest and apoptosis. Cancer Biol Ther. 2006; 5:1015-21.
25. Barada KA, Mourad FH, Sawah SI, et al. Up-regulation of nerve growth factor and interleukin-10 in inflamed and non-inflamed intestinal segments in rats with experimental colitis. Cytokine. 2007; 37:236-45.
26. Chen L, Li Y, Fu Y, et al. Role of deregulated microRNAs in breast cancer progression using FFPE tissue. PLoS One. 2013; 8:e54213.
27. Roy M, Marchetti D. Cell surface heparan sulfate released by heparanase promotes melanoma cell migration and angiogenesis. J Cell Biochem. 2009; 106:200-9.
28. Zhang Y, Li L, Wang Y, et al. Downregulating the expression of heparanase inhibits the invasion, angiogenesis and metastasis of human hepatocellular carcinoma. Biochem Biophys Res Commun. 2007; 358: 124-9.
29. Zheng L, Jiang G, Mei H, et al. Small RNA interference-mediated gene silencing of heparanase abolishes the invasion, metastasis and angiogenesis of gastric cancer cells. BMC Cancer. 2010; 10: 33.
30. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002; 296: 550-3.
31. H. Kawasaki, K. Taira. Short hairpin type of dsRNAs that are controlled by tRNA (Val) promoter significantly induce RNAi-mediated gene silencing in the cytoplasm of human cells. Nucleic Acids Res. 2003; 31: 700-7.
32. Bridge AJ, Pebernard S, Ducraux A, et al. Induction of an interferon response by RNAi vectors in mammalian cells. Nature Genet. 2003; 34:263-4.
33. Jackson AL, Bartz SR, Schelter J, et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol. 2003; 21: 635-7.
34. Zeng Y, Wagner EJ, Cullen BR. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell. 2002; 9: 1327-33.
35. Chang K, Elledge SJ, Hannon GJ. Lessons from nature: microRNA-based shRNA libraries. Nat Methods. 2006; 3: 707-14.
36. Zhou H, Xia XG, Xu Z. An RNA polymerase II construct synthesizes short-hairpin RNA with a quantitative indicator and mediates highly efficient RNAi. Nucleic Acids Res. 2005; 33:e62.
37. Chung KH, Hart CC, Al-Bassam S, et al. Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/miR-155. Nucleic Acids Res. 2006; 34: e53.
38. Dickins RA, McJunkin K, Hernando E, et al. Tissue-specific and reversible RNA interference in transgenic mice. Nat Genet. 2007; 39:914-21.
39. Li L, Lin X, Khvorova A, et al. Defining the optimal parameters for hairpin-based knockdown constructs. RNA. 2007; 13: 1765-74.
40. Boudreau RL, Monteys AM, Davidson BL. Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. RNA. 2008; 14:1834-44.
41. Boudreau RL, Martins I, Davidson BL. Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol Ther. 2009; 17:169-75.
42. Sledz CA, Holko M, de Veer MJ, et al. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol. 2003;: 5834-9.
43. Kleinman ME, Yamada K, Takeda A, et al. Sequence-and target-independent angiogenesis suppression by siRNA via TLR3. Nature. 2008; 452: 591-7.
44. Bergé M, Bonnin P, Sulpice E, et al. Small interfering RNAs induce target-independent inhibition of tumor growth and vasculature remodeling in a mouse model of hepatocellular carcinoma. Am J Pathol. 2010; 177: 3192-201.
45. Stojdl DF, Lichty B, Knowles S, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med. 2000; 6: 821-5.
46. Wollmann G, Robek MD, van den Pol AN. Variable deficiencies in the interferon response enhance susceptibility to vesicular stomatitis virus oncolytic actions in glioblastoma cells but not in normal human glial cells. J Virol. 2007; 81:1479-91.
47. Chawla-Sarkar M, Leaman DW, Jacobs BS, et al. Resistance to interferons in melanoma cells does not correlate with the expression or activation of signal transducer and activator of transcription 1 (Stat1). J Interferon Cytokine Res. 2002; 22: 603-13.
48. Bae SI, Cheriyath V, Jacobs BS, et al. Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL. Oncogene. 2008; 27: 490-8.
49. Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/ short hairpin RNA pathways. Nature. 2006; 441: 537-41.
50. Beer S, Bellovin DI, Lee JS, et al. Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult mice. Mol Ther. 2010; 18:161-70.
51. Bridge AJ, Pebernard S, Ducraux A, et al. Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet. 2003; 34: 263-4.
52. Pebernard S, Iggo RD. Determinants of interferon-stimulated gene induction by RNAi vectors. Differentiation. 2004; 72: 103-11.
53. Anscher MS. Targeting the TGF-beta1 pathway to prevent normal tissue injury after cancer therapy. Oncologist. 2010; 15: 350-9.
54. Pedroza M, Schneider DJ, Karmouty-Quintana H, et al. Interleukin-6 contributes to inflammation and remodeling in a model of adenosine mediated lung injury. PLoS One. 2011; 6(7): e22667.
55. Yamada M, Kubo H, Kobayashi S, et al. Interferon-gamma: a key contributor to hyperoxia-induced lung injury in mice. Am J Physiol Lung Cell Mol Physiol. 2004; 287: L1042-7.
56. Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008; 456: 980-4.
57. Denby L, Ramdas V, McBride MW, et al. miR-21 and miR-214 are consistently modulated during renal injury in rodent models. Am J Pathol, 2011; 179: 661-72.
58. Liu G, Friggeri A, Yang Y, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med. 2010; 207: 1589-97.
59. Davis BN, Hilyard AC, Lagna G, et al. SMAD proteins control DROSHA mediated microRNA maturation. Nature. 2008; 454: 56e61.
60. Chung AC, Dong Y, Yang W, et al. Smad7 suppresses renal fibrosis via altering expression of TGF-β/Smad3-regulated microRNAs. Mol Ther. 2013; 21:388-98.
61. Garbacki N, Di Valentin E, Huynh-Thu VA, et al. MicroRNAs profiling in murine models of acute and chronic asthma: a relationship with mRNAs targets. PLoS One. 2011; 6: e16509.